Shareholders meeting

Ref: ADL/SE/2026-27/42 September 2, 2026 To, To, Listing/ Compliance Department Listing/ Compliance Department BSE Limited National Stock Exchange of India Limited, Phiroze Jeejeebhoy Towers, “Exchange Plaza”, Plot No. C/1, Dalal Street, G Block Bandra - Kurla Complex, Mumbai – 400 001 Bandra (East), Mumbai – 400051 BSE CODE: 524348 NSE SYMBOL: AARTIDRUGS Dear Sir/Madam, Sub: Notice of 41st Annual General Meeting and Annual Report of the Company for the Financial Year 2025-26 Ref: Regulation 34 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Please find enclosed herewith the Annual Report of the Company for the Financial Year 2025-26, along with the Notice of the 41st Annual General Meeting (AGM) of the Company scheduled to be held on Saturday, September 26, 2026 at 11:00 a.m. (IST) through Video Conferencing (VC) / Other Audio Visual Means (OAVM). In accordance with the MCA Circulars and SEBI Circulars, the Notice of the AGM along with the Annual Report is being sent through electronic mode to those shareholders whose email address(es) are registered with the Company/ Registrar & Transfer Agent/ Depositories/ Depository Participants. Further, the Company has also initiated sending letters containing the weblink of the Annual Report for FY 2025-26 to the shareholders whose e-mail address(es) are not registered. The Notice of 41st AGM of the Company along with the Annual Report for the Financial Year 2025-26 is available on the website of the Company at web link: https://www.aartidrugs.com/reports-fillings-annual-reports. Kindly take the same on record. Thanking you, Yours faithfully, FOR AARTI DRUGS LIMITED RUSHIKESH DEOLE COMPANY SECRETARY & COMPLIANCE OFFICER ICSI M. No.: F12932 n d ation. Mahendra Industrial Estate Ground Floor, Road No. 29 Plot No. 109-D, Sion (East) Mumbai - 400 022, Maharashtra Tel. No.: +91 22-2401 9025 Annual Report 2025-26 Fax: +91 22 2407 3462/+91 22 2407 0144 Website: www.aartidrugs.com Aarti Drugs Limited Annual Report 2025-26 Corporate Overview Disclaimer: This document contains statements about expected future events and financials of Aarti Drugs Limited (‘Aarti Drugs’), ‘the Company’ which are ‘forward looking’. By their nature, forward-looking statements require the Company to make assumptions and are subject to inherent risks and uncertainties. There is a significant risk that the assumptions, predictions, and other forward-looking statements may not prove to be accurate. Readers are cautioned not to place undue reliance on forward-looking statements as several factors could cause actual future results and events to differ materially from those expressed in the forward-looking statements. Accordingly, this document is subject to the disclaimer and qualified in its entirety by the assumptions, qualifications and risk factors referred to in the Management Discussion and Analysis section of this Annual Report. 05-10 Key Highlights of the Year 2 Corporate Snapshot 4 Our Presence 6 Milestones 8 From the Chairman’s Desk 10 Product Portfolio 14 Research and Development 18 Financial Performance 20 Key Strategies 22 Stakeholder Engagement 24 Environment 26 Social 30 Governance 40 Meet the Board 44 Awards and Achievements 48 Corporate Information 50 Statutory Reports 351-15 Management Discussion and Analysis Directors’ Report 64 Corporate Governance Report 88 Business Responsibility & Sustainability Reporting Financial Statements 172-451 Standalone 155 Consolidated 213 Annual General Meeting 903-272 Investor Information A Stronger Foundation. Equity ISIN INE767A01016 A Better Future. CIN L37060MH1984PLC055433 BSE Code 524348 NSE Symbol AARTIDRUGS AGM Date September 26, 2026 AGM Venue/Mode VC/OAVM FY 2025-26 was a year in which 300 tonnes per month, creating a This progress has strengthened what Aarti Drugs began translating several stronger base for further portfolio Aarti Drugs can manufacture, where years of capability-building into a integration. During the year, USFDA, it can operate and how effectively it more integrated platform for growth. UK MHRA and EU GMP approvals can execute. Against pricing pressures, Investments across manufacturing, expanded the Company's readiness geopolitical disruptions and elevated backward integration, regulatory to serve regulated markets, which input costs, this ability to build greater readiness, portfolio expansion and contributed 73% of revenues during integration, market access and financial discipline are increasingly the year. The upcoming 24.4 MWp solar operating flexibility provides a stronger coming together to support the next power project further advances the platform for the future. phase of the business. Company's transition towards captive renewable energy. These initiatives, The Sayakha facility commenced together with a record-low debt-to- commercial production during the year, equity ratio, reflect the Company’s adding methylamines to the Company’s disciplined approach to capital manufacturing chain and further deployment while continuing to strengthening the integration of its invest in long-term growth and Metformin portfolio. At Tarapur, Salicylic operational capabilities. Acid production scaled beyond Notice 272 For more investor-related information, please visit: https://www.aartidrugs.com/ Or simply scan the QR code: Annual Report 2025-26 Key Highlights of the Year Momentum in Motion FY 2025-26 marked an important transition for Aarti Drugs as years of strategic investments began translating into tangible operational progress. From ramping up the Sayakha facility to stabilising the Tarapur Salicylic Acid plant, expanding regulated market revenues and securing key global regulatory approvals, the Company strengthened the capabilities that will drive its next phase of growth. Financial Operational Sustainability 2,568 14 11 Crores Total Revenue Manufacturing Facilities Zero Liquid Discharge (ZLD) Facilities 38 1,59,500 ~ % + 2,200 Export Revenue Sq. m. Plant Area Employees 312 80 Crores + 50,000 EBITDA Finished Products Lives Impacted through Our CSR Activities 195 6,876 Crores MT (Note: The numbers are on consolidated basis) PAT Monthly Capacity API Molecules Products Under Development/ Pipeline (API + Finished Dosages) Corporate Overview Aarti Drugs Limited Annual Report 2025-26 Corporate Snapshot e s t Prod u Turning Potential into ar e r Our Mission Progress etronidazole in Seek global market leadership Focus on growth and development of the product With over four decades of experience and an established Continue to create winning culture, operating in highest presence across APIs, pharmaceutical intermediates, standards of ethics and values with co-operation among specialty chemicals and formulations, Aarti Drugs Limited competitors (‘Aarti Drugs’, ‘ADL’, ‘We’ or ‘The Company’) is a leading pharmaceutical manufacturer. Backed by integrated Strive for excellence in customer service, quality and R&D manufacturing facilities, internationally recognised regulatory accreditations and strong in-house R&D Our Vision capabilities, the Company continues to strengthen process efficiencies, advance product development and deliver We shall become the first-choice vendor of bulk drugs and achieve a leadership high-quality solutions across regulated and semi-regulated ne o f the Le a di position by: markets. O ducer M etformin HCl hn eg csu uvir sdi tn c eco run sss ti ost me in st q du sa ol li uty a on nd ati nm de sl ey rd ve icli ev e tory a et ec to cm hp ae nt gi it niv ge p er qi uce irements Global Leadership P ld Aim at customer orientation through continuous technology upgrade, high business ethics, and new product development Adopt processes supported by proven technologies, which are cost Nimesulide effective and safe Choose the best and the most flexible manufacturing practices and methods Ketoconazole Certifications Metronidazole Benzoate ISO 9001: 2015 - Quality Management System Tinidazole ISO 14001:2015 - Environmental Fluoro [Showing first 8,000 characters — download PDF for full document]